TY - JOUR
T1 - Endocrinopathies and cancer cachexia
AU - Dev, Rony
AU - Del Fabbro, Egidio
AU - Dalal, Shalini
N1 - Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Purpose of reviewCancer cachexia cannot be easily reversed by standard nutritional support and interventions directed at underlying metabolic derangements may be needed to prevent or reverse cachexia and maintain healthy body composition. The following review will highlight the contribution and potential therapeutic interventions for insulin resistance, alterations in ghrelin signaling, and hypogonadism in cancer patients.Recent findingsIn addition to decreased caloric intake, chronic inflammation, and altered metabolism of glucose, proteins and lipids, endocrine abnormalities can propagate weight loss or changes in body composition in cancer patients.SummaryCancer cachexia, loss of muscle mass with or without the loss of fat mass, is a multifactorial syndrome, which is associated with increased morbidity and mortality. Currently, limited therapeutic options for the treatment of weight loss in cancer patients exist, which lead to clinically meaningful improvements in weight gain and performance status. Treatment directed at underlying insulin resistance, low testosterone, and altered ghrelin sensitivity, in the future, may lead to potential therapeutic options for loss of lean body mass and cancer cachexia.
AB - Purpose of reviewCancer cachexia cannot be easily reversed by standard nutritional support and interventions directed at underlying metabolic derangements may be needed to prevent or reverse cachexia and maintain healthy body composition. The following review will highlight the contribution and potential therapeutic interventions for insulin resistance, alterations in ghrelin signaling, and hypogonadism in cancer patients.Recent findingsIn addition to decreased caloric intake, chronic inflammation, and altered metabolism of glucose, proteins and lipids, endocrine abnormalities can propagate weight loss or changes in body composition in cancer patients.SummaryCancer cachexia, loss of muscle mass with or without the loss of fat mass, is a multifactorial syndrome, which is associated with increased morbidity and mortality. Currently, limited therapeutic options for the treatment of weight loss in cancer patients exist, which lead to clinically meaningful improvements in weight gain and performance status. Treatment directed at underlying insulin resistance, low testosterone, and altered ghrelin sensitivity, in the future, may lead to potential therapeutic options for loss of lean body mass and cancer cachexia.
KW - cachexia
KW - cancer
KW - ghrelin
KW - hypogonadism
KW - insulin resistance
UR - http://www.scopus.com/inward/record.url?scp=85072577178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072577178&partnerID=8YFLogxK
U2 - 10.1097/SPC.0000000000000464
DO - 10.1097/SPC.0000000000000464
M3 - Review article
C2 - 31567482
AN - SCOPUS:85072577178
SN - 1751-4258
VL - 13
SP - 286
EP - 291
JO - Current opinion in supportive and palliative care
JF - Current opinion in supportive and palliative care
IS - 4
ER -